moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Company profile
Ticker
MLTX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Helix Acquisition Corp
SEC CIK
Corporate docs
Subsidiaries
MoonLake Immunotherapeutics AG • MoonLake Immunotherapeutics Ltd • MNLK Immunotherapeutics, Unipessoal Lda, a private limited company incorporated ...
MLTX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Regulation FD Disclosure
11 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
29 Feb 24
8-K
Regulation FD Disclosure
26 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
14 Nov 23
8-K
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
6 Nov 23
Latest ownership filings
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
5 Mar 24
4
da Silva Jorge Santos
29 Feb 24
4
Kristian Reich
29 Feb 24
4
da Silva Jorge Santos
23 Feb 24
4
Kristian Reich
22 Feb 24
4
da Silva Jorge Santos
20 Feb 24
4
Kristian Reich
16 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
SC 13G/A
Merck Healthcare KGaA
15 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 318.17 mm | 318.17 mm | 318.17 mm | 318.17 mm | 318.17 mm | 318.17 mm |
Cash burn (monthly) | 61.21 mm | (no burn) | 4.33 mm | 4.65 mm | 3.08 mm | 3.50 mm |
Cash used (since last report) | 422.59 mm | n/a | 29.87 mm | 32.10 mm | 21.29 mm | 24.18 mm |
Cash remaining | -104.43 mm | n/a | 288.30 mm | 286.07 mm | 296.88 mm | 293.98 mm |
Runway (months of cash) | -1.7 | n/a | 66.7 | 61.5 | 96.3 | 83.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 121 |
Opened positions | 49 |
Closed positions | 13 |
Increased positions | 32 |
Reduced positions | 25 |
13F shares | Current |
---|---|
Total value | 3.20 tn |
Total shares | 78.08 mm |
Total puts | 879.40 k |
Total calls | 66.90 k |
Total put/call ratio | 13.1 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 21.75 mm | $1.13 bn |
BVF | 21.75 mm | $1.24 tn |
Cormorant Asset Management | 8.14 mm | $464.10 bn |
FMR | 3.40 mm | $193.64 bn |
T. Rowe Price | 2.12 mm | $120.85 bn |
Citadel Advisors | 2.03 mm | $115.96 bn |
Avoro Capital Advisors | 2.00 mm | $114.00 bn |
Adage Capital Partners GP, L.L.C. | 1.95 mm | $111.30 bn |
T. Rowe Price Investment Management | 1.21 mm | $69.31 bn |
FHI Federated Hermes Inc - Ordinary Shares | 1.08 mm | $61.80 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | da Silva Jorge Santos | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | No | Yes | 55.89 | 4,740 | 264.92 k | 2,982,814 |
28 Feb 24 | da Silva Jorge Santos | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | No | Yes | 55 | 56,065 | 3.08 mm | 2,987,554 |
28 Feb 24 | Kristian Reich | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | No | Yes | 55 | 28,090 | 1.54 mm | 41,981 |
28 Feb 24 | Kristian Reich | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | Yes | Yes | 55 | 31,910 | 1.76 mm | 2,925,573 |
27 Feb 24 | da Silva Jorge Santos | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | No | Yes | 55 | 62,810 | 3.45 mm | 3,043,619 |
27 Feb 24 | Kristian Reich | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | No | Yes | 55 | 29,431 | 1.62 mm | 70,071 |
27 Feb 24 | Kristian Reich | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | Yes | Yes | 55 | 29,491 | 1.62 mm | 2,957,483 |
21 Feb 24 | Kristian Reich | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | No | Yes | 55.3 | 569 | 31.47 k | 99,502 |
21 Feb 24 | Kristian Reich | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | Yes | Yes | 55.31 | 509 | 28.15 k | 2,986,974 |
20 Feb 24 | Kristian Reich | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | No | Yes | 57.43 | 10,000 | 574.30 k | 100,071 |
News
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target
23 Apr 24
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target
11 Apr 24
Needham Reiterates Buy on MoonLake, Maintains $66 Price Target
9 Apr 24
Goldman Sachs Initiates Coverage On MoonLake with Neutral Rating, Announces Price Target of $62
2 Apr 24
Wedbush Reiterates Outperform on MoonLake, Maintains $92 Price Target
13 Mar 24
Press releases
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
10 Apr 24
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
10 Mar 24